Cargando…
The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: A 12-week open-label pilot study
Agitation is one of the most devastating behavioral symptoms in demented patients but there is little evidence about effective and safe pharmacotherapy. We aimed to determine the effectiveness and safety of mirtazapine in treatment of agitated patients with Alzheimer’s disease (AD). The consecutive...
Autores principales: | Cakir, Sibel, Kulaksizoglu, Isin Baral |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626919/ https://www.ncbi.nlm.nih.gov/pubmed/19183787 |
Ejemplares similares
-
Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study
por: Uccellini, Davide, et al.
Publicado: (2006) -
Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study
por: Song, Hoo Rim, et al.
Publicado: (2015) -
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial
por: Banerjee, Sube, et al.
Publicado: (2021) -
Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine
por: Correia, Ana Salomé, et al.
Publicado: (2021) -
Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao, Kei, et al.
Publicado: (2013)